The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has been added tAndMarkets.com's offering.This report describes and explains the ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

TD Cowen raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $155 and keeps a Buy rating on the shares. The company ...

AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United ...

Class A shares underperformed the MSCI ACWI ex USA Index. During the quarter, we initiated four new positions and exited one ...

The news caused a significant decline in the price of FTAI Aviation stock. On January 15, 2025, the price of the company's stock fell 24%, from a closing price of $153.29 per share on January 14, 2025 ...

In October 2024, Novartis announced that based on its review of 48-week data from the Phase 3 MANIFEST-2 study, longer follow-up time is needed to determine the regulatory path for pelabresib in ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

TD Cowen adjusted its outlook on Axsome Therapeutics (NASDAQ:AXSM), a $6.16 billion market cap company, by increasing the price target to $190 from the previous $155, while maintaining a Buy rating on ...

Securities exhibited confidence in Axsome Therapeutics (NASDAQ:AXSM) by increasing the company's price target from $137.00 to $195.00. The firm has maintained an Outperform rating on the stock. This ...

Camtek (Nasdaq: CAMT; TASE: CAMT) rose 2.16% for the biggest rise on the Tel Aviv 35 Index today. Nova Ltd. (Nasdaq: NVMI; TASE: NVMI) rose 1.26%, Energean plc (LSE: ENOG; TASE: ENOG) rose 1.23% and ...